CN113613659A - 用于治疗患有慢性肾病的糖尿病患者的卡格列净 - Google Patents

用于治疗患有慢性肾病的糖尿病患者的卡格列净 Download PDF

Info

Publication number
CN113613659A
CN113613659A CN202080024296.4A CN202080024296A CN113613659A CN 113613659 A CN113613659 A CN 113613659A CN 202080024296 A CN202080024296 A CN 202080024296A CN 113613659 A CN113613659 A CN 113613659A
Authority
CN
China
Prior art keywords
canagliflozin
patient
renal
chronic kidney
kidney disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080024296.4A
Other languages
English (en)
Chinese (zh)
Inventor
N·R·罗森塔尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN113613659A publication Critical patent/CN113613659A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080024296.4A 2019-03-26 2020-03-25 用于治疗患有慢性肾病的糖尿病患者的卡格列净 Pending CN113613659A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962823719P 2019-03-26 2019-03-26
US201962823724P 2019-03-26 2019-03-26
US201962823722P 2019-03-26 2019-03-26
US62/823722 2019-03-26
US62/823719 2019-03-26
US62/823724 2019-03-26
US201962835550P 2019-04-18 2019-04-18
US62/835550 2019-04-18
PCT/EP2020/058415 WO2020193652A1 (en) 2019-03-26 2020-03-25 Canagliflozin for the treatment of diabetic patients with chronic kidney disease

Publications (1)

Publication Number Publication Date
CN113613659A true CN113613659A (zh) 2021-11-05

Family

ID=70050106

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080024296.4A Pending CN113613659A (zh) 2019-03-26 2020-03-25 用于治疗患有慢性肾病的糖尿病患者的卡格列净

Country Status (8)

Country Link
US (1) US20220160739A1 (https=)
EP (1) EP3946367A1 (https=)
JP (2) JP2022526914A (https=)
CN (1) CN113613659A (https=)
CA (1) CA3134786A1 (https=)
MX (1) MX2021011711A (https=)
TW (1) TW202103709A (https=)
WO (1) WO2020193652A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022216870A1 (en) * 2021-04-07 2022-10-13 Ur-1 Therapeutics, Inc. Urat1 inhibitor, pharmaceutical compositions and uses thereof
CN117085009B (zh) * 2023-10-20 2024-01-30 首都医科大学附属北京天坛医院 卡格列净对急性缺血性卒中的治疗作用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105939728A (zh) * 2014-01-31 2016-09-14 詹森药业有限公司 用于治疗和预防肾病和脂肪肝病的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531660T3 (es) 2003-08-01 2015-03-18 Mitsubishi Tanabe Pharma Corporation Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
UY30730A1 (es) 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105939728A (zh) * 2014-01-31 2016-09-14 詹森药业有限公司 用于治疗和预防肾病和脂肪肝病的方法
US20160339047A1 (en) * 2014-01-31 2016-11-24 Janssen Pharmaceutica Nv Methods for the treatment and prevention of renal disorders and fatty liver disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HIROYUKI TAKASHIMA ET AL.: "Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial", 《DIAB VASC DIS RES》, 20 June 2018 (2018-06-20), pages 1 - 4 *
J-F YALE ET AL.: "Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease", 《DIABETES, OBESITY AND METABOLISM》, vol. 16, no. 10, 31 October 2014 (2014-10-31), pages 1016 - 1027, XP055700544, DOI: 10.1111/dom.12348 *
MEG J JARDINE ET AL.: "The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics", 《AM J NEPHROL》, vol. 46, no. 6, 1 December 2017 (2017-12-01), pages 462 - 472 *

Also Published As

Publication number Publication date
JP2025111453A (ja) 2025-07-30
EP3946367A1 (en) 2022-02-09
WO2020193652A1 (en) 2020-10-01
JP2022526914A (ja) 2022-05-27
US20220160739A1 (en) 2022-05-26
MX2021011711A (es) 2021-10-22
TW202103709A (zh) 2021-02-01
CA3134786A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
Kovesdy Management of hyperkalemia: an update for the internist
TW201249432A (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
CN112789041A (zh) 用于降低血清尿酸的组合物
JP2025111453A (ja) 慢性腎臓病を有する糖尿病患者を治療するためのカナグリフロジン
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
HK40062581A (en) Canagliflozin for the treatment of diabetic patients with chronic kidney disease
TWI888729B (zh) 包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－甲酸之醫藥組成物
Pucci et al. SGLT2 inhibitors for kidney protection in children: expanding horizons beyond endocrinology
CN101229372A (zh) 一种治疗高血压的药物组合物
CN106344591B (zh) 奥柳氮钠作为制备防治高尿酸血症和痛风的药物的应用
JP2005531492A (ja) 高リスク患者のｉｉ型糖尿病を低減させる方法
EA047563B1 (ru) Канаглифлозин для лечения больных диабетом пациентов с хроническим заболеванием почек
EA050266B1 (ru) Фармацевтическая композиция, включающая 1-(3-циано-1-изопропилиндол-5-ил)пиразол-4-карбоновую кислоту
JPH01216931A (ja) 血中尿酸濃度低減用治療剤
Tablets et al. Pr SANDOZ SAXAGLIPTIN
Tablets et al. PrAPO-SAXAGLIPTIN
TW202033199A (zh) 化合物ａ與化合物ｂ聯合在製備治療痛風或高尿酸血症的藥物中的用途
HK40044975A (en) Joint use of compound a and compound b in preparation of medications for treatment of gout or hyperuricemia
HK40102231A (zh) 包含1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的药物组合物
Orynchak et al. RENOPROTECTIVE EFFECTS OF COMBINED ANTIHYPERTENSIVE TREATMENT IN HYPERTENSIVES WITH NEPHROPATHY: PP. 15.430
Agent PrTEVA-SAXAGLIPTIN
TW201103544A (en) Pharmaceutical composition and application thereof
KR20090042976A (ko) 글루코즈 수준을 저하시키는 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40062581

Country of ref document: HK